Immunotherapy and Immune Evasion in Prostate Cancer

Cancers

Archana Thakur¹  Ulka Vaishampayan¹ 

[1] Department of Oncology, Wayne State University, Detroit, MI 48201, USA

关键词: prostate cancer;    immunotherapy;    vaccine;    castrate resistant prostate cancer;    bispecific antibody;   

DOI  :  10.3390/cancers5020569

来源: mdpi

【 摘 要 】

Metastatic prostate cancer remains to this day a terminal disease. Prostatectomy and radiotherapy are effective for organ-confined diseases, but treatment for locally advanced and metastatic cancer remains challenging. Although advanced prostate cancers treated with androgen deprivation therapy achieves debulking of disease, responses are transient with subsequent development of castration-resistant and metastatic disease. Since prostate cancer is typically a slowly progressing disease, use of immune-based therapies offers an advantage to target advanced tumors and to induce antitumor immunity. This review will discuss the clinical merits of various vaccines and immunotherapies in castrate resistant prostate cancer and challenges to this evolving field of immune-based therapies.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.